Skip to content
Screener

Roivant Sciences ROIV Operating Lease Liabilities

Operating Lease Liabilities at other companies

Moderna logo
ModernaMRNA
$638M-4.2%
Regenxbio logo
RegenxbioRGNX
$61.6M-11.6%
Revvity logo
RevvityRVTY
$142.28M-9.2%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$10.6M+24.9%

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25.37B+219%
Enterprise value$25.4B+219%
P/S3,368×+3,026×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0001635088-26-000090
Line itemJune 30, 2026March 31, 2026
Income tax payable74,18245,689
Other current liabilities3,213583
Total current liabilities283,603281,244
Operating lease liabilities, noncurrent94,76896,291
Income tax payable, noncurrent38,670
Other liabilities6,25370
Total liabilities384,624416,275
Commitments and contingencies (Note 10)

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's operating lease liabilities?
Roivant Sciences (ROIV) reported operating lease liabilities of $94.77M in Q2 2026.
How has Roivant Sciences's operating lease liabilities changed year-over-year?
Roivant Sciences's operating lease liabilities increased by 5.0% year-over-year, from $90.29M to $94.77M.
What is the long-term trend for Roivant Sciences's operating lease liabilities?
Over 5 years (2020 to 2025), Roivant Sciences's operating lease liabilities has grown at a 9.1% compound annual growth rate (CAGR), from $62.38M to $96.29M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Roivant Sciences's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude